In the News

Share
1740 News Items found
Dr. Debyani Chakravarty
Why New Precision Oncology Cancer Treatments Benefit Patients of Some Ancestries More Than Others
Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.
Luc Morris
New AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Many Cancers
Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who will benefit from immune checkpoint inhibitors using only routine blood tests and clinical data.
Close-up of hand holding glass of red wine.
Does Drinking Alcohol Cause Cancer? Learn About the Risks
Learn more about the link between drinking alcohol and the risk of developing cancer.
Seungjae Lee and Eric Lai
The Secret Life of ALAS1: How a Basic Science Discovery Could Pave the Way for Better siRNA Therapies
New findings by researchers at MSK and their collaborators at the Icahn School of Medicine point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer.
A researcher working in an MSK lab
MSK Research Highlights, December 18, 2024
New MSK research uncovers clues about how cells control a key DNA repair protein; develops a new method for studying gene amplifications in cancer; sheds new light on tumor suppressor genes; shows MSK-IMPACT® could be used for HLA genotype screening to predict response to cellular therapies; identifies a possible strategy to overcome immune evasion in ovarian cancer; and finds strong support for telemedicine visits among cancer patients.
An immunofluorescence image of an aged mouse liver
Top Cancer Research Advances at MSK in 2024
MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.
Amy Speck
Top Cancer Treatment Advances at MSK in 2024
Learn about some of the most important advances in cancer treatment and clinical trials at MSK in 2024.
Four people who were successfully treated for rectal cancer in a clinical trial at Memorial Sloan Kettering are seen posing outdoors with the trial’s two principal investigators.
Rectal Cancer Disappears After Experimental Use of Immunotherapy, Now an FDA Designated Breakthrough Therapy
Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
Article
MSK medical oncologist Komal Jhaveri.
Imlunestrant Stops Progression of ER+, HER2- Advanced Breast Cancer That Resists Standard Therapy
Read about a new treatment for people with some ER+, HER2- advanced breast cancers.
Support
Nurse practitioner Amy Devigne
MSK Program Keeps a Close Watch on Long-Term Lung Cancer Survivors
An MSK program helps lung cancer survivors stay healthy following successful treatment for their disease.